Unraveling the soul of autoimmune diseases: Pathogenesis, diagnosis and treatment adding dowels to the puzzle

Immunologic Research

Volumn 56, Issue 2-3, 2013, Pages 200-205

  Colafrancesco, S ^a,b   Agmon Levin, N ^a,c   Perricone, C ^a,b   Shoenfeld, Y ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aluminum; Autoantibodies; Autoimmune inflammatory syndrome induced by adjuvants (ASIA); Autoimmunity; Genetic; Infections; Silicone

Indexed keywords

ALUMINUM; AUTOANTIBODY; PENTRAXIN 3; SILICONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VACCINE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENETIC DISORDER; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOASSAY; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE; MENINGOENCEPHALITIS; MOSAICISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COMPLEMENT SYSTEM PROTEINS; ENVIRONMENTAL EXPOSURE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOTHERAPY;

EID: 84879549617     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8429-4     Document Type: Review

References (70)

1. de Carvalho JF, Pereia RM, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front Biosci. 2009;1:501-9.
2. Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Lab Invest Suppl. 2001;235:3-15. (Pubitemid 33044511)
3. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Pouria S, Shoenfeld Y. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev. 2012.
4. Perricone C, Agmon-Levin N, Ceccarelli F, Valesini G, Anaya JM, Shoenfeld Y. Genetics and autoantibodies. Immunol Res. 2013. doi: 10.1007/s12026-013- 8396-9.
5. Linn-Rasker SP, van Der Helm-van Mil AH, van Gaalen FA, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLADRB1 shared epitope allels. Ann Rheum Dis. 2006;65:366-71. (Pubitemid 43268227)
6. Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res. 2013. doi: 10.1007/s12026-013-8398-7.
7. Bieber V, Cohen AD, Freud T, Agmon-Levin N, Gertel S, Amital H. Autoimmune smoke and fire-coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: a cross-sectional analysis. Immunol Res. 2013. doi: 10.1007/s12026-013-8395-x.
8. Bogdanos DP, Smyk DS, Invernizzi P, Rigopoulou EI, Blank M, Sakkas L, Pouria S, Shoenfeld Y. Tracing environmental markers of autoimmunity: introducing the infectome. Immunol Res. 2013. doi: 10.1007/s12026-013-8399-6.
9. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity. Trends Immunol. 2009;30:409-14.
10. Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol. 2009;5:648-52.
11. Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus. 2009;18:1127-8.
12. Harnett W, Harnett MM. Molecular basis of worm-induced immunomodulation. Parasite Immunol. 2006;28(535-543):12.
13. Fischer S, Agmon-Levin N, Shapira Y, Porat Katz BS, Graell E, Cervera R, Stojanovich L, Gómez Puerta JA, Sanmartí R, Shoenfeld Y. Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunol Res. 2013. doi: 10.1007/s12026-013-8402-2.
14. Weinbrand-Goichberg J, Segal I, Ovadia A, Levine A, Dalal I Eosinophilic esophagitis: an immune-mediated esophageal disease. Immunol Res. 2013. doi: 10.1007/s12026-013-8394-y.
15. Dolcino M, Zanoni G, Bason C, Tinazzi E, Boccola E, Valletta E, Contreas G, Lunardi C, Puccetti A. A subset of anti-rotavirus antibodies directed against the viral protein VP7 predicts the onset of celiac disease and induces typical features of the disease in the intestinal epithelial cell line T84. Immunol Res. 2013. doi: 10.1007/s12026-013-8420-0.
16. Lidar M, Shinar Y, Goldberg M, Ben-Zvi I, Langevitz P, Livneh A. E148Q MEFV mutation carriage and longevity in individuals of Ashkenazi origin. Immunol Res. 2013. doi: 10.1007/s12026-013-8414-y.
17. Shoenfeld Y, Agmon-Levin N. "ASIA" - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4-8.
18. Shoenfeld Y, Agmon-Levin N. Abstract of: 'ASIA' - autoimmune (auto-inflammatory) syndrome induced by adjuvant- a new syndrome to be defined. In: Abstracts of selected invited lectures. Lupus. 2011;20:340-7.
19. Shoenfeld Y. Autoimmune (autoinflammatory) syndrome induced by adjuvants provides a diagnostic framework for enigmatic conditions. The Rheumatologist. 2011;6:26-32.
20. Shoenfeld Y, Hughes GRV, Agmon-Levin N. The spectrum of ASIA: 'autoimmune (auto-inflammatory) syndrome induced by adjuvants'. Lupus. 2012;21:118-20.
21. Perricone C, Agmon-Levin N, Valesini G, Shoenfeld Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego. Joint Bone Spine. 2012;79:1-3.
22. Levy Y, Rotman-Pikielny P, Ehrenfeld M, Shoenfeld Y. Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature. Lupus. 2009;18:1226-32.
23. Israeli E. Gulf War Syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvant (ASIA). Lupus. 2012;21:190.
24. Authier FJ, Sauvat S, Champey J, Drogou I, Coquet M, Gherardi RK. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis Rheum. 2003;48:569-72. (Pubitemid 36278027)
25. Israeli E. The new model of sick building syndrome: inclusion in ASIA or Shoenfeld's syndrome. Mod Rheumatol. 2012;22:802.
26. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217-25.
27. Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, Shoenfeld Y. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus. 2009;18:1192-7.
28. Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol. 2000;18:181-4. (Pubitemid 30208260)
29. Perricone C, Ceccarelli F, Valesini G. An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev. 2011;10(10):599-608.
30. Perricone R, Perricone C, Shoenfeld Y. Autoimmunity: when the immune system becomes the self-ish giant. Autoimmun Rev. 2011;10(10):575-6.
31. Selmi C, Battezzati PM, Tishler M, Shoenfeld Y, Gershwin ME. Vaccines in the 21st century: the genetic response and the innocent bystander. Autoimmun Rev. 2005;4:79-81. (Pubitemid 40255614)
32. Cerpa-Cruz S, Paredes-Casillas P, Landeros Navarro E, Bernard-Medina AG, Martínez-Bonilla G, Gutiérrez-Ureña S. Adverse events following immunization with vaccines containing adjuvants. Immunol Res. 2013. doi: 10.1007/s12026-013-8400-4.
33. Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013. doi: 10.1007/s12026-013-8403-1.
34. Harrington CR, Wischik CM, McArthur FK, Taylor GA, Edwardson JA, Candy JM. Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet. 1994;343:993-7. (Pubitemid 24122606)
35. Lopes MM, Caldas LQA. Young children with austim spectrum disorders: can aluminium bodyburden cause metabolism disruption? Toxicol Lett. 2011;205S:S60-179.
36. Banks WA, Kastin AJ. Aluminum-induced neurotoxicity: alterations in membrane function at the blood-brain barrier. Neurosci Biobehav Rev. 1989;13:47-53. (Pubitemid 19215169)
37. Prat AK, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia. 2001;36:145-55. (Pubitemid 33055903)
38. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008;180:5402-12.
39. Luján L, Pérez M, Salazar E, Alvarez N, Gimeno M, Pinczowski P, Irusta S, Santamaría J, Insausti N, Cortés Y, Figueras L, Cuartielles I, Vila M, Fantova E, Chapullé JL. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. Immunol Res. 2013. doi: 10.1007/s12026-013-8404-0.
40. Khan Z, Combadière C, Authier FJ, Itier V, Lux F, Exley C, Mahrouf-Yorgov M, Decrouy X, Moretto P, Tillement O, Gherardi RK, Cadusseau J. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med. 2013;4(11):99.
41. Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21:184-9.
42. Carvalho JF, Barros SM, Branco JC. ASIA or Shoenfeld's syndrome: highlighting different perspectives for diffuse chronic pain. Acta Reumatol Port. 2011;36:10-2.
43. Cohen Tervaert JW. Silicon exposure and vasculitis. In: Uversky VN, Kretsinger RH, Permyakov EA (eds). Encyclopedia of metalloproteins. Springer Science + Business Media, LLC. 2012. doi: 10.1007/978-1-4614-1533-6.
44. Vera-Lastra O, Medina G, Cruz-Dominguez Mdel P, Ramirez P, Gayosso-Rivera JA, Anduaga-Dominguez H, Lievana-Torres C, Jara LJ. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome). Lupus. 2012;21:128-35.
45. Shoaib BO, Patten BM. Human adjuvant disease: presentation as a 414 multiple slcerosis-like syndrome. South Med J. 1996;89:179-88. (Pubitemid 26055946)
46. Nancy AL, Shoenfeld Y. Chronic fatigue syndrome with auto-antibodies - the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev. 2008;8:52-5.
47. Cohen Tervaert JW, Kappel RM. Silicone implant incompatibility syndrome (SIIS): A frequent cause of ASIA (Shoenfeld's syndrome). Immunol Res. 2013. doi: 10.1007/s12026-013-8401-3.
48. Tozzoli R, Sorrentino MC, Bizzaro N. Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple autoimmune syndromes and overlap syndromes): a challenge for the autoimmunologist. Immunol Res. 2013. doi: 10.1007/s12026-013-8418-7.
49. Damoiseaux J. Autoantibodies in the grocery shop: does quantity matter? Immunol Res. 2013. doi: 10.1007/s12026-013-8419-6.
50. Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D, Perricone R. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev. 2011;10(10):617-23.
51. Di Muzio G, Perricone C, Ballanti E, Kroegler B, Greco E, Novelli L, Conigliaro P, Cipriani P, Giacomelli R, Perricone R. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int J Immunopathol Pharmacol. 2011;24(2):357-66.
52. Szekanecz Z, Szabó Z, Zeher M, Soós L, Dankó K, Horváth I, Lakos G. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res. 2013. doi: 10.1007/s12026-013-8425-8.
53. Zafrir Y, Gilburd B, Carrasco MG, Kivity S, Sánchez- Castañón M, López-Hoyos M, Mandel M, Szmyrka M, Shoenfeld Y, Agmon-Levin N. Evaluation of an automated chemiluminescent immunoassay kit for antinuclear antibodies in autoimmune diseases. Immunol Res. 2013. doi: 10.1007/s12026-013-8416-9.
54. Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, Chantarangkul V, Bertero T, De Micheli V, Borghi MO, Meroni PL. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013. doi: 10.1007/s12026-013-8421-z.
55. Ballanti E, Perricone C, Greco E, Ballanti M, Di Muzio G, Chimenti MS, Perricone R. Complement and autoimmunity. Immunol Res. 2013. doi: 10.1007/s12026-013-8422-y.
56. Chimenti MS, Perricone C, Graceffa D, Di Muzio G, Ballanti E, Guarino MD, Conigliaro P, Greco E, Kroegler B, Perricone R. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30(1):23-30.
57. Kundzer AV, Volkova MV, Bogdanos DP, Rödiger S, Schierack P, Generalov I, Nevinsky GA, Roggenbuck D. Deoxyribonuclease activity of polyclonal IgGs: a putative serological marker in patients with spondyloarthritides. Immunol Res. 2013. doi: 10.1007/s12026-013-8424-9.
58. Padeh S, Farzam N, Chayen G, Gerstein M, Berkun Y. Pentraxin 3 is a marker of early joint inflammation in patients with juvenile idiopathic arthritis. Immunol Res. 2013. doi: 10.1007/s12026-013-8417-8.
59. Atzeni F, Turiel M, Hollan I, Meroni P, Sitia S, Tomasoni L, Sarzi-Puttini P. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev. 2010;9(12):845-8.
60. Khattri S, Zandman-Goddard G. Statins and autoimmunity. Immunol Res. 2013. doi: 10.1007/s12026-013-8409-8.
61. Katzav A, Bina H, Aronovich R, Chapman J. Treatment for experimental autoimmune neuritis with clodronate (Bonefos). Immunol Res. 2013. doi: 10.1007/s12026-013-8406-y.
62. Le Dantec C, Alonso R, Fali T, Montero E, Devauchelle V, Saraux A, Pers JO, Renaudineau Y. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunol Res. 2013. doi: 10.1007/s12026-013-8423-x.
63. Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A. Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunol Res. 2013. doi: 10.1007/s12026-013-8411-1.
64. Nalotto L, Iaccarino L, Zen M, Gatto M, Borella E, Domenighetti M, Punzi L, Doria A. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res. 2013. doi: 10.1007/s12026-013-8408-9.
65. Lora V, Bonaguri C, Gisondi P, Sandei F, Battistelli L, Russo A, Melegari A, Trenti T, Lippi G, Girolomoni G. Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res. 2013. doi: 10.1007/s12026-013-8410-2.
66. Voswinkel J, Francois S, Gorin NC, Chapel A. Gastro-intestinal autoimmunity: preclinical experiences and successful therapy of fistulizing bowel diseases and gut Graft versus host disease by mesenchymal stromal cells. Immunol Res. 2013. doi: 10.1007/s12026-013-8397-8.
67. Proal AD, Albert PJ, Marshall TG, Blaney GP, Lindseth IA. Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis. Immunol Res. 2013. doi: 10.1007/s12026-013-8413-z.
68. Hershko AY, Scheiman-Elazari A, Aamar S, Naparstek Y. Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study. Immunol Res. 2013. doi: 10.1007/s12026-013-8412-0.
69. Coloma Bazán E, Donate López C, Moreno Lozano P, Cervera R, Espinosa G. Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res. 2013. doi: 10.1007/s12026-013-8407-x.
70. Szekanecz Z, Meskó B, Poliska S, Váncsa A, Szamosi S, Végh E, Simkovics E, Laki J, Kurkó J, Besenyei T, Mikecz K, Glant TT, Nagy L. Pharmacogenetics and pharmacogenomics in rheumatology. Immunol Res. 2013. doi: 10.1007/s12026-013-8405-z.